Thymoquinone and 3HQ synergy inhibits CTX-M-15 ESBL
Biomolecules and Biomedicine · 2025
DOI: 10.17305/bb.2025.12431 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules and Biomedicine, 2025. Verfasst von Karem Ibrahem und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. Hauptthemen laut MEDLINE: Benzoquinones, beta-Lactamases, Anti-Bacterial Agents, Quinoxalines. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Bacterial infections remain a significant cause of mortality worldwide, further aggravated by the escalating issue of antibiotic resistance. Extended-Spectrum Beta-Lactamases (ESBLs) pose a substantial challenge, capable of hydrolyzing various beta-lactam antibiotics. The slow pace of drug discovery, coupled with the rapid emergence of drug-resistant bacteria, underscores the urgent need for innovative therapeutic solutions. Thymoquinone (TQ), derived from the seeds of Nigella sativa, has demonstrated notable antibacterial activity against Gram-negative bacteria, including Escherichia coli and Pseudomonas aeruginosa. Previous research has established the efficacy of quinoxaline derivatives, such as 3-hydrazinoquinoxaline-2-thiol (3HQ), against Methicillin-Resistant Staphylococcus aureus (MRSA). This study investigates the potential synergy between 3HQ and TQ against various clinical strains of ESBL. The minimum inhibitory concentrations (MICs) of TQ and 3HQ were evaluated against 18 clinical ESBL strains, revealing MIC values ranging from 16 to 128 µg/mL for both compounds. Furthermore, the interaction between TQ and 3HQ was assessed using a checkerboard assay, which demonstrated a 100% synergistic interaction, with a fractional inhibitory concentration index (FICI) of less than 0.5 against the ESBL strains. Docking and molecular dynamics simulations indicated that TQ exhibits a strong binding affinity and interaction profile comparable to that of RPX-7063. In contrast, 3-hydrazinoquinoxaline-2-thiol targets a different active site, potentially enhancing thymoquinone's binding efficiency. Collectively, these compounds may effectively inhibit CTX-M-15, as evidenced by their docking scores and interaction profiles. Further investigations, including in vivo studies, are essential to validate these findings. This research suggests a promising strategy for developing more effective treatments for ESBL infections, emphasizing the need for in vivo validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
- Department of Clinical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; Center of Research Excellence for Drug Research and Pharmaceutical Industries, King Abdulaziz Uni…
- Department of Clinical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; Department of Clinical Microbiology Laboratory, King Abdulaziz University Hospital, Jeddah, Saudi…
- Department of Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
- Center of Research Excellence for Drug Research and Pharmaceutical Industries, King Abdulaziz University, Jeddah, Saudi Arabia; Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi…
- Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
Zitieren
APA
Ibrahem, K., Alrabia, M., Fatani, A., Alharthi, S. E. M., Asfour, H. Z., Alhakamy, N. A., Niyazi, H. A., Altayb, H. N., Sait, A. M., Day, P. J. R., & Alfadil, A. (2025). Thymoquinone and 3HQ synergy inhibits CTX-M-15 ESBL. Biomolecules and Biomedicine. https://doi.org/10.17305/bb.2025.12431
Vancouver
Ibrahem K, Alrabia M, Fatani A, Alharthi SEM, Asfour HZ, Alhakamy NA, et al. Thymoquinone and 3HQ synergy inhibits CTX-M-15 ESBL. Biomolecules and Biomedicine. 2025. doi:10.17305/bb.2025.12431
BibTeX
@article{Ibrahem2025,
author = {Ibrahem, Karem and Alrabia, Mohammad and Fatani, Asif and Alharthi, Sameer E M and Asfour, Hani Zakareya and Alhakamy, Nabil A and Niyazi, Hatoon A and Altayb, Hisham N and Sait, Ahmad M and Day, Philip J R and Alfadil, Abdalbagi},
title = {Thymoquinone and 3HQ synergy inhibits CTX-M-15 ESBL},
journal = {Biomolecules and Biomedicine},
year = {2025},
doi = {10.17305/bb.2025.12431}
}
EUVIMED